Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

Published on June 16, 2026 at 2:45 pm by Talha Qureshi in News

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Could Skyrocket in 2026. Wall Street is bullish on the stock as all 14 analysts covering the stock maintain a Buy rating, and their 12-month average price target suggests more than 280% upside from the current level.

Recently, on June 8, H.C. Wainwright reiterated its Buy rating and $25 price target on AtaiBeckley Inc. (NASDAQ:ATAI). The rating comes after the firm met the company’s management on June 2. The discussion reinforced the firm’s conviction that BPL-003, which is an intranasal formulation of 5-MeO-DMT, remains the primary driver for the company. Moreover, management told the firm that they are preparing to launch their Phase 3 program, called ReConnection, targeting treatment-resistant depression.

H.C. Wainwright highlighted several practical advantages of BPL-003’s profile, including an 8 mg dose that balances efficacy and tolerability, a short in-clinic session duration, flexible retreatment options, and clinic economics that fit neatly into a two-hour interventional psychiatry model. The firm believes that these positive points make it operationally attractive for treatment centers.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders.